Acasunlimab

艾卡苏利单抗

Report date: 2026/02/12 20:00:14

Base Information

Drug NameAcasunlimab
Drug Alias NamePD-L1x4-1BBDuoBody-PD-L1x4-1BBGEN1046BNT-311
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSkin MelanomaSolid tumoursUterine Cervical Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[19] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiontech SeGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenmab A/SBiontech Se
Active IndicationsN/A
Inactive IndicationsSkin MelanomaSolid tumoursUterine Cervical Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A